FibroGen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FGEN research report →
Range $28 – $28
Price Chart
About the company
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases.
- CEO
- Thane Wettig
- IPO
- 2014
- Employees
- 225
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on FGEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.69M
- P/E
- 0.21
- PEG
- 0.00
- P/S
- 1.40
- P/B
- -0.25
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
- Gross Margin
- 19.59%
- Op Margin
- -1099.92%
- Net Margin
- 657.67%
- ROE
- -104.75%
- ROIC
- -538.71%
Latest fiscal year · YoY change
- Revenue
- $6.44M-78.3%
- Gross Profit
- $0-100.0%
- Op Income
- $-45,895,000
- Net Income
- $183.45M+485.6%
- EPS
- $45.37+9552.1%
- OCF Growth
- +96.5%
- FCF Growth
- +96.5%
- 52W High
- $21.95
- 52W Low
- $4.85
- 50D MA
- $9.14
- 200D MA
- $8.84
- Beta
- 0.77
- RSI (14)
- 57
- Avg Volume
- 33.23K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kyntra Bio used the quarter to pivot away from FG-3246 after weak interim efficacy and refocus on roxadustat in lower-risk MDS, while also improving its financing structure and cash outlook.· November 16, 2026
- FG-3246/FG-3180 was terminated after a planned interim analysis failed to meet the efficacy threshold needed to continue.
- The company is now focused on phase III roxadustat in lower-risk MDS, targeting initiation in Q1 2027, subject to a strategic partnership or external capital raise.
- NovaQuest financing was amended to cut the maximum payment obligation from $125 million to $65 million and leave only $15 million of remaining capped payments.
- Management highlighted roxadustat post-hoc data in high transfusion burden patients, including transfusion-independence rates of 36% vs 7% over the first 28 weeks and 45% vs 13% over 52 weeks.
- Cash equivalents, investments, and accounts receivable were $44.1 million at September 30, and management now expects cash runway into 2028.
Third-quarter 2026 total revenue was $1.8 million versus $1.1 million in the same period of 2025. Total operating costs and expenses were $14.6 million versus $6.5 million a year ago, with R&D at $8.3 million versus $1.2 million and SG&A at $5.8 million versus $5.3 million. The company reported net income from continuing operations of $0.2 million, or $0.04 per basic and diluted share, versus a net loss of $13.1 million, or $3.25 per share, in Q3 2025, driven by a $14 million gain on debt restructuring from the NovaQuest amendment. As of September 30, cash equivalents, investments, and accounts receivable totaled $44.1 million. Management reiterated that roxadustat phase III initiation is targeted for Q1 2027, subject to either a strategic partnership or external capital raise, and that the interim analysis is expected in 2H 2028 with primary analysis in 1H 2030.
Thane Wettig framed the quarter as a major strategic pivot: the company is exiting FG-3246/FG-3180 and becoming a more focused rare-disease company centered on roxadustat. He said the decision was driven by insufficient interim efficacy, but argued the lower-risk MDS opportunity remains compelling because of unmet need, oral dosing, and the phase III design informed by MATTERHORN post-hoc data and FDA input. His tone was candid about the setback but confident about the new direction, repeatedly emphasizing focus, simplification, and a near-term path to phase III if financing is secured.
David DeLucia focused on the balance-sheet and financing cleanup. He said the NovaQuest amendment reduced the maximum aggregate payment obligation from $125 million to $65 million, after an accelerated upfront payment of $42.6 million in Q3, leaving $15 million of capped payments funded from 50% of covered Astellas royalty revenue outside Japan. He noted the amendment produced an internal rate of return of over 26% based on the revised obligations. On the income statement, he cited $1.8 million of revenue, $14.6 million of operating costs and expenses, and $44.1 million in cash equivalents, investments, and accounts receivable, and said the company now expects runway into 2028 despite the need to fund the roxadustat phase III start.
Analysts pressed on whether Kyntra will disclose FG-3246 data and whether CD46 expression may explain the failure; management said disclosure will happen in some form but timing and format are unclear, and that CD46 expression has not yet been analyzed, though the overall data did not support continued development. Questions also focused on whether roxadustat’s smaller data set could complicate partnering or financing; management said the phase II/post-hoc package is sufficient to move ahead and that another small study would likely add time and cost without much incremental learning. On the phase III plan, management said operations are largely complete, enrollment is assumed at 201 patients over 24 months across 100-110 sites, and the interim analysis is strictly for futility, not acceleration. Later questions addressed thromboembolic risk and the choice of the high-transfusion-burden population; management said FDA accepted the prior dosing/titration approach, they tightened eligibility criteria, and they view the 4+ unit subgroup as both a clinically meaningful and commercially attractive target with lower placebo response.
Management now has a cleaner story: one asset has been cut, the balance sheet has been simplified, and roxadustat is moving toward a clearly defined phase III program with FDA alignment on dose. They also pointed to encouraging efficacy signals in a hard-to-treat high-transfusion-burden group, including responses across RS-negative and RS-positive patients and durability measures that management believes support the phase III rationale.
The biggest risk is that the company still needs either a strategic partner or new capital to start the phase III trial, so the timeline is not fully under its control. The FG-3246 termination also shows the company can lose programs when interim data disappoint, and the roxadustat strategy still relies on post-hoc data from a relatively small subgroup, with acknowledged Grade 3 and thrombotic/cardiovascular imbalances in the study.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.6%
- Shares Outstanding
- 4.05M
- Float Shares
- 3.58M
of shares held by institutions
33 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 181.97K | ▼ 2.27K |
| Two Sigma Advisers, LP | 22.81K | ▲ 22.81K |
| Cibc Private Wealth Group LLC | 287 | 0 |
Held by 11 ETFs
Biggest fund positions in FGEN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 25, 22 | Wettig Thane | other | 1,988 |
| Aug 22, 22 | Wettig Thane | other | 1,820 |
| Dec 31, 22 | Wettig Thane | other | 0 |
| Sep 22, 22 | Wettig Thane | other | 655 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FGEN coverage
Recent articles, reports, and earnings notes.
No research on FGEN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FGEN report →Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com · Mar 9
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
globenewswire.com · Feb 23
FibroGen (NASDAQ:FGEN) Stock Crosses Above Fifty Day Moving Average – Here’s Why
defenseworld.net · Jan 24
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
globenewswire.com · Jan 7
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript
seekingalpha.com · Nov 10
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 10
FibroGen to Report Third Quarter 2025 Financial Results
globenewswire.com · Nov 3
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
globenewswire.com · Sep 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.